personalized viral neoantigen vaccine

A personalized viral neoantigen vaccine is a customized cancer immunotherapy designed to stimulate a patient's immune system against unique mutations found in their specific tumor. The platform typically utilizes viral vectors, such as Great Ape Adenovirus (GAd) or Modified Vaccinia Ankara (MVA), to deliver a payload of multiple tumor-specific neoantigens (nAgs) identified through genomic sequencing of the patient's biopsy. Upon administration, the viral vectors induce a robust and polyfunctional immune response, primarily characterized by the activation and expansion of neoantigen-specific CD8+ effector memory T cells. This approach aims to provide precise antitumor activity and long-term immunological memory. Clinical and preclinical studies, such as those conducted by NousCom, evaluate these vaccines in neoadjuvant and adjuvant settings, often in combination with immune checkpoint inhibitors like anti-PD-1 to enhance efficacy in checkpoint-resistant or early-stage cancers.

Other names

personalized viral vaccineviral vector nAg vaccinemultiepitope nAg vaccinepersonalized neoantigen vaccine